Global Small Molecule Drug Discovery Market to reach USD 55.03 billion by 2027.Global Small Molecule Drug Discovery Market is valued approximately at USD 32.15 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 8.05% over the forecast period 2021-2027. Targeted drug delivery involves small molecules entering through the cell membrane and function on a specific cellular organelle or protein. Because of their low molecular weight, small molecules medicines may easily penetrate cells. Because of their small size, simple translation to oral form, and cost-effectiveness, these compounds outperform monoclonal antibodies and other large molecule drugs. The growing use of small molecule medicines in the treatment of chronic diseases is driving up demand for small molecule pharmaceuticals on the market. According to the 2019 heart disease and Stroke Statistics by governments, it is estimated to affect 116.4 million individuals in the United States, or 46 percent of the adult population. According to the American Cancer Society, around 1.8 million new cancer cases are expected to be diagnosed globally in 2020, with approximately 606,520 cancer deaths. As the number of chronic diseases rises, so will the demand for treatments, resulting in the market's rapid expansion. However, High Drug Development cost may impede market growth over the forecast period of 2021-2027.

North America currently dominates the global small molecule drug discovery market, and this leadership is expected to continue in the future years. Rising incidence of numerous chronic illnesses, such as cardiovascular disease, cancer, and others, as well as growing number of approval of novel small molecules in the region, are the key drivers driving the market's growth. Furthermore, in small molecule drug development, industry companies are employing technologically advanced technologies.

Major market player included in this report are:
Boehringer Ingelheim GmbH
21st Century Therapeutics Inc.
Agilent Technologies Inc.
Bristol-Myers Squibb Company
Acacia Pharma Gr
GlaxoSmithKline PLC
Gilead Sciences Inc.
Johnson & Johnson
AstraZeneca
4SC-Discovery




The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product Therapeutic Areas of key players. The detailed segments and sub-segment of the market are explained below:

By Therapeutic Area:
Oncology
Central Nervous System
Cardiovascular
Respiratory
Metabolic Disorders
Gastrointestinal
Other Therapeutic Areas
By Process/Phase:
Target ID/Validation
Hit Generation and Selection
Lead Identification
Lead Optimization
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Small Molecule Drug Discovery Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors